Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
复制标题
DOI：
10.1517/13543784.2013.761972
复制
发表时间：
2013-03-01
影响因子：
6.1
通讯作者：
Lockhart, Albert Craig
中科院分区：
文献类型：
--
作者：
Desai, Monica Dandona;Saroya, Bikramajit Singh;Lockhart, Albert Craig
导言：胃肠道(GI)恶性肿瘤占美国所有癌症相关死亡的近四分之一，约占全球所有癌症相关死亡的30%。使用联合细胞毒疗法可以适度改善存活率，但大多数胃肠道癌患者的预后和长期存活率仍然很差。在某些胃肠道恶性肿瘤中，针对HER受体家族成员的治疗对患者的治疗产生了积极的影响。在这篇综述中，我们讨论了HER受体家族在食道胃、肝胆、胰腺癌和结直肠癌中的重要性，并解释了支持使用单抗(MAbs)和小分子酪氨酸激酶抑制剂(TKIs)来抑制HER激活及其下游事件的原理，这些事件有助于肿瘤的增殖、迁移和生存。专家意见：尽管最近取得了进展，但GI癌症的治疗仍然具有挑战性。针对HER受体家族的治疗已经在这些恶性肿瘤中进行了广泛的研究，但结果不一致。这些药物对肿瘤的不同反应背后的原因仍不确定。我们认为，需要更多的研究来确定生物标志物，以帮助确定对给定治疗更敏感的患者群体。
Introduction: Gastrointestinal (GI) malignancies account for nearly one-fourth of all cancer-related deaths in the United States and approximately 30% of all cancer-related deaths worldwide. Use of combination cytotoxic therapy offers a modest improvement in survival, but the prognosis and long-term survival of most patients with GI cancer remains poor. In certain GI malignancies, therapies that target members of the HER family of receptors have positively impacted patient care.Areas covered: In this review, we discuss the significance of the HER family of receptors in esophagogastric, hepatobiliary, pancreatic, and colorectal cancers and explain the rationale supporting the use of monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs) to inhibit HER activation and downstream events that contribute to tumor proliferation, migration, and survival.Expert opinion: Despite recent advances, the treatment of GI cancers remains challenging. Therapies targeting the HER family of receptors have been extensively studied in these malignancies with inconsistent results. The rationale behind varied tumor responses with these agents remains uncertain. We believe that additional studies are needed to identify biomarkers that could help identify a population of patients who would be more responsive to a given therapy.